Generic Davids and Innovator Goliaths

  • Posted on: 20 December 2013
  • By: admin

 

PharmaTutor (December- 2013)
ISSN: 2347 - 7881

 

Received On: 16/12/2013; Accepted On: 19/12/2013; Published On: 20/12/2013

 

Author: Amit Gangwal
Department of Pharmacognosy,
Smriti college of pharmaceutical education, Indore, Madhya Pradesh, India
gangwal.amit@gmail.com

 

ABSTRACT: Patents provide an incentive to the pharmaceutical industry to invest in the development of new medicines to treat diseases that are currently untreatable or incurable, and provide options when patients develop resistance to older drugs. Around the world it has been a challenge for last one or two decades to innovate concepts and mechanisms to hasten the drug development schemes/process, while augmenting dereplication ways in a full proof manner to save time, man power and financial input. High failure rate at any stage in drug development process is bothering and evoking various tools to be discussed like never before. The pharmaceutical industries world over, are in a period of crisis due to the poor number of approved drug molecules relative to the high levels of R&D investment. The drug industry is facing major scientific and strategic challenges. Moreover competition from generic giants is giving tough challenge to established products owing to end of patent rights. The concerns are further aggravated by couple of decisions announced by Indian courts (Nexavar® followed by long time pending battle of Gleevac®). These two decrees by Indian courts were not ruled in the favor of pharma giants; Bayer and Novartis respectively. Millions are dying in various part of world, owing to their inability to purchase the Elite Drugs, because of intellectual property rights. In this article various pros and cons have been discussed pertaining to generic medicines and patent fights of innovators world over.

 

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML]